PPARA and metabolic dysfunction-associated steatotic liver disease: These findings indicate that the circRNA_0046366 or circRNA_0046366/miR-34a/PPAR pathways can represent epigenetic mechanisms underlying hepatic steatosis and may become a therapeutic alternative in NAFLD treatment [139].